stockrow
Friday 6 November 2026
Export IMCC’s income statement to Excel — free account
IM Cannabis Corp.
IMCC Healthcare Drug Manufacturers Specialty & Generic
IM Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 0.66% from fiscal 2024.
- Revenue
- −40.3%
- EPS
- −385.7%
- Free cash flow
- −266.8%
- Total debt
- −64.7%
Quarter to June 2026, against a year earlier
0.59
0.00
0.00%
Follow IMCC
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.05 | 0.06 | 0.15 | 0.25 | |
P/FCF ratio |
0.00 | 18.46 | 1.72 | 0.00 | |
P/Operating CF |
(1.87) | (16.16) | 1.95 | (3.69) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 2.99 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.04 | 0.07 | 0.12 | 0.24 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.63) | 18.21 | 1.37 | (3.26) | |
EV/FCF |
(2.57) | 20.18 | 1.36 | (3.25) | |
Quick Ratio |
0.29 | 0.30 | 0.42 | 0.35 | |
Current Ratio |
0.56 | 0.55 | 0.67 | 0.82 | |
Net Debt/EBITDA |
0.66 | (0.22) | 0.26 | 0.17 | |
Debt/Assets |
2.68% | 6.05% | 4.91% | 3.78% | |
Debt/Equity |
(0.12) | (0.28) | (0.43) | 0.39 | |
Asset Turnover |
1.39 | 1.52 | 1.53 | 1.15 | |
Operating CF/Net income |
0.26 | 0.08 | (0.56) | 0.95 | |
Capex/Depreciation |
0.00 | (0.01) | (0.01) | (0.01) | |
Interest Coverage |
(0.72) | (2.01) | (7.00) | (6.09) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
47.37% | 35.66% | 25.54% | 27.49% | |
Intangible Assets out of Total Assets |
0.10 | 0.12 | 0.10 | 0.15 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.01% | |
Graham Net Nets |
(6.50) | (4.56) | (1.53) | (0.65) | |
Graham Number |
151.06 | 171.23 | 155.52 | 0.00 | |
Earnings Yield |
(1,524.40%) | (620.49%) | (140.68%) | (43.49%) | |
Free Cash Flow Yield |
(31.23%) | 5.42% | 57.99% | (29.25%) | |
Revenue per Share |
17.76 | 32.05 | 79.55 | 62.06 | |
Operating CF per Share |
(2.69) | (0.69) | 21.38 | (15.60) | |
Capex per Share |
0.00 | (0.02) | (0.02) | (0.02) | |
Free Cash Flow per Share |
(2.70) | (0.71) | 21.35 | (15.62) | |
Cash per Share |
4.07 | 4.25 | 16.77 | 10.38 | |
Shareholders Equity per Share |
(13.17) | (18.92) | (18.32) | 19.28 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(13.17) | (18.92) | (18.32) | 19.28 | |
Free Cash Flow |
(0.83) | (0.14) | 3.02 | (2.53) | |
Working Capital |
(9.43) | (9.19) | (8.06) | (4.93) | |
Capital Expenditures |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Current Asset Value |
(10.12) | (9.99) | (9.02) | (6.07) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
7.00 | 8.41 | 8.92 | 10.88 | |
Average Payables |
7.46 | 8.57 | 8.39 | 8.67 | |
Average Inventory |
2.35 | 2.62 | 2.70 | 5.22 | |
Average Assets |
23.76 | 24.28 | 25.66 | 32.45 | |
Average Common Equity |
(0.56) | (0.76) | (0.15) | 3.10 |
Columns are period end dates · fundamentals updated 2 Nov 2026